Galectin-7 Impairs Placentation and Causes Preeclampsia Features in Mice
Ellen Menkhorst,Wei Zhou,Leilani L. Santos,Sarah Delforce,Teresa So,Kate Rainczuk,Hannah Loke,Argyro Syngelaki,Swati Varshney,Nicholas Williamson,Kirsty Pringle,Morag J. Young,Kypros H. Nicolaides,Yves St-Pierre,Evdokia Dimitriadis,Eva Dimitriadis
DOI: https://doi.org/10.1161/hypertensionaha.120.15313
IF: 9.8968
2020-09-16
Hypertension
Abstract:Download figure Download PowerPoint Preeclampsia is a serious pregnancy-induced disorder unique to humans. The etiology of preeclampsia is poorly understood; however, poor placental formation is thought causal. Galectin-7 is produced by trophoblast and is elevated in first-trimester serum of women who subsequently develop preeclampsia. We hypothesized that elevated placental galectin-7 may be causative of preeclampsia. Here, we demonstrated increased galectin-7 production in chorionic villous samples from women who subsequently develop preterm preeclampsia compared with uncomplicated pregnancies. In vitro, galectin-7 impaired human first-trimester trophoblast outgrowth, increased placental production of the antiangiogenic sFlt-1 splice variant, sFlt-1-e15a , and reduced placental production and secretion of ADAM12 (a disintegrin and metalloproteinase12) and angiotensinogen. In vivo, galectin-7 administration (E8–E12) to pregnant mice caused elevated systolic blood pressure, albuminuria, impaired placentation (reduced labyrinth vascular branching, impaired decidual spiral artery remodeling, and a proinflammatory placental state demonstrated by elevated IL1β, IL6 and reduced IL10), and dysregulated expression of renin-angiotensin system components in the placenta, decidua, and kidney, including angiotensinogen, prorenin, and the angiotensin II type 1 receptor. Collectively, this study demonstrates that elevated galectin-7 during placental formation contributes to abnormal placentation and suggests that it leads to the development of preeclampsia via altering placental production of sFlt-1 and renin-angiotensin system components. Targeting galectin-7 may be a new treatment option for preeclampsia.
peripheral vascular disease